Screener
Monopar Therapeutics MNPR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | March 31, 2026 | December 31, 2025* |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $52,544,263 | $61,833,552 |
| Investments | 84,948,677 | 78,565,491 |
| Other current assets | 250,903 | 63,745 |
| Total current assets | 137,743,843 | 140,462,788 |
| Operating lease right-of-use asset | 239,882 | 254,921 |
| Total assets | $137,983,725 | $140,717,709 |
Document
FAQ
- What is Monopar Therapeutics's cash & equivalents?
- Monopar Therapeutics (MNPR) reported cash & equivalents of $52.54M in Q1 2026.
- How has Monopar Therapeutics's cash & equivalents changed year-over-year?
- Monopar Therapeutics's cash & equivalents increased by 32.3% year-over-year, from $39.71M to $52.54M.
- What is the long-term trend for Monopar Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Monopar Therapeutics's cash & equivalents has grown at a 30.1% compound annual growth rate (CAGR), from $16.61M to $61.83M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Monopar Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude